2018 Virtual Symposium (CME concluded): Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice

Death from CV disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death. Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. In addition, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of evidence is accumulating on the effectiveness of several antihyperglycemic agents to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM.

In this virtual symposium, recorded from the 13th Annual Cardiometabolic Health Congress, experts will utilize a unique, infographic teaching format to review the latest cardiovascular outcomes studies of current antihyperglycemic therapies and compare the risks vs benefits as well as how to incorporate them into an individualized treatment plan for clinicians who treat patients with T2DM who are at a high risk for CVD.

CV Comorbidities in T2DM Patients

Presenter: Deepak L. Bhatt, MD, MPH

Review of Recent CVOTs Results and Clinical Implications

Presenter: Lawrence Blonde, MD

Individualization of Treatment in T2DM Patients with CVD

Presenter: Harold E. Bays, MD

CVOT Data in Your Clinical Practice: Patient Case and Audience Q&A

Chairperson: Robert H. Eckel, MD

Presenter: Deepak L. Bhatt, MD, MPHLawrence Blonde, MDHarold E. Bays, MD